Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) shot up 2% on Thursday . The company traded as high as $28.02 and last traded at $27.75, with a volume of 66,613 shares. The stock had previously closed at $27.21.

BPMC has been the topic of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $41.00 price objective on shares of Blueprint Medicines Corp. in a report on Tuesday, August 9th. Canaccord Genuity initiated coverage on shares of Blueprint Medicines Corp. in a report on Friday, August 5th. They issued a “buy” rating and a $26.00 price objective on the stock. TheStreet raised shares of Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a report on Friday, July 29th. Zacks Investment Research raised shares of Blueprint Medicines Corp. from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a report on Thursday, August 11th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, August 9th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Blueprint Medicines Corp. presently has a consensus rating of “Buy” and an average price target of $29.43.

The company’s market capitalization is $739.21 million. The stock’s 50-day moving average price is $22.83 and its 200 day moving average price is $19.07.

Blueprint Medicines Corp. (NASDAQ:BPMC) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.03. During the same quarter in the previous year, the business posted ($0.81) EPS. The company earned $7.07 million during the quarter, compared to analyst estimates of $4.41 million. The company’s revenue was up 163.0% on a year-over-year basis. Equities research analysts forecast that Blueprint Medicines Corp. will post ($3.05) earnings per share for the current fiscal year.

In other Blueprint Medicines Corp. news, CEO Jeffrey W. Albers sold 17,000 shares of Blueprint Medicines Corp. stock in a transaction on Monday, August 8th. The shares were sold at an average price of $22.86, for a total transaction of $388,620.00. Following the sale, the chief executive officer now owns 76,494 shares in the company, valued at $1,748,652.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

An institutional investor recently raised its position in Blueprint Medicines Corp. stock. RS Investment Management Co. LLC raised its position in Blueprint Medicines Corp. (NASDAQ:BPMC) by 17.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 740,310 shares of the company’s stock after buying an additional 109,878 shares during the period. RS Investment Management Co. LLC owned about 2.73% of Blueprint Medicines Corp. worth $19,500,000 at the end of the most recent reporting period.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.